Get started

PHARMA

Moderna Progress on all VaccinesThe statistics are between $184 - $219(1 Year) Its Financial Health is very strong. Why not wait till Moderna makes greater progress and finds It Resistance Again at $450 Moderna has many projects running. So if we see progress in some of the projects in the next Years, we will see a great price rise. I believe it won't be difficult to reach its older resistance again, around $450. Disclaimer: Just my Idea! Find your Trading Ideas and learn and study more!
NASDAQ:MRNALong
by TraderMentorX
Sanofi - Pharming for profits?Sanofi Short Term We look to Buy at 95.00 (stop at 91.90) The medium term bias remains bullish. Levels close to the 50% pullback level of 93.25 found buyers. Previous support located at 93.08. Further upside is expected and we look to set longs in early trade. Our profit targets will be 104.35 and 110.00 Resistance: 95.16 / 98.22 / 104.35 Support: 93.25 / 93.08 / 92.78 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
EURONEXT:SANLong
by Saxo
SUNPHARMA (Trade the Trend) - BullishSUNPHARMA - Sun Pharmaceutical Industries Ltd. NSE:SUNPHARMA After Q4 Results we saw a good sell-off in Sunpharma, yet the price hardly moved much Shanghvi stated "Our India business continues to grow faster than the market, leading to an increase in market share. We continue to focus on expanding our global specialty business, growing all our businesses, and improving operational efficiencies," stated. The company said its board has proposed a final dividend of Rs 3 per share for FY22. One can plan a long position between 835 to 840 with a strict SL of Rs 825 for short term trading (01 to 02 weeks) and SL if the price moves below 825 (Daily candle close) for long term swing trading (greater than 2 weeks) Short Term targets are up to - 886 Long Term Target is up to - 929 Risk Reward for this trade is very good #Learn&earn #Wealth #Editor's Choice #trending #Weathmagnet candlestick analysis, candlestick stock pattern Do Support by Liking and Commenting on our Post as it motivates us to post more such ideas The chart is for study purposes only!! Kindly consult your Financial Advisor before investing any money
NSE:SUNPHARMALong
by harshnisar45
5
The big "Legalize It"Fundamentals: + Weed + Established pharma and re-creational contacts. + Key moment for the "Legalize it" movement Opinion: Cron and Aurora canabis are the main names in the publicly traded cannabis's industry. As governments attempt to fight inflation while walking the recession line, it becomes a "Win-Win" for legalization and governments. A number of countries still have restrictions on cannabis but whilst fighting inflation and hunting for taxable income, the next 24 months may prove to be the most legaly accommodating towards this new industry. This week Thailand made the move. The idea is that they wont be the last! #Long Notes on how I personally use my charts/NFA: Each level L1-L3 and TP1-TP3 has a deployment percentage. The idea is to flag these levels so I can buy 11% at L1 , 28% at L2 and if L3 deploy 61% of assigned dry powder. The same in reverse goes for TP. TP1: 61%, TP2:28% and TP3:11%. If chart pivots between TP's, in-between or in Between Sell levels these percentages are still respected. I like to use the trading range to accumulate by using this tactic. Just my personal way of using this. This is not intended or made to constitute any financial advice. This is not intended or made to constitute any financial advice. FED Macro Situation Consideration: All TP's are drawn within the context of a return to FED neutral policy. I do not expect these levels to be reached before tightening is over. NOT INVESTMENT ADVICE I am not a financial advisor. The Content in this TradingView Idea is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained within this idea constitutes a solicitation, recommendation, endorsement, or offer to buy or sell any securities or other financial instruments in this or in in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. All Content on this idea post is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in the idea/post constitutes professional and/or financial advice, nor does any information on the idea/post constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. You alone assume the sole responsibility of evaluating the merits and risks associated with the use of any information or other Content on the idea/post before making any decisions based on such information.
NASDAQ:CRONLong
by TheBitcoinGeneration
1
Pharma firm SIGA cashes in on monkeypox scareNew York-based pharmaceutical firm SIGA Technologies (NASDAQ:SIGA) is among the companies to benefit from the growing threat of monkeypox, recently pushing its shares to an almost decade-high after the company obtained approval in Europe to use its TPOXX antiviral drug for the treatment of monkeypox. Smallpox jabs vs monkeypox On May 19, the World Health Organization declared that vaccines used against smallpox — before the virus was eradicated in 1980 — can be used to fight monkeypox. SIGA already won approval from the US Food and Drug Administration in 2018 to distribute its oral TPOXX capsules as a treatment against smallpox even when there were no reports of confirmed or possible cases of smallpox at the time. US advances in vaccine orders Most recently, SIGA on Thursday secured another approval from the FDA for the intravenous (IV) formulation of TPOXX for patients who are unable to swallow the drug’s oral variant. SIGA said the IV formulation of TPOXX has already been cited in the recent US president’s budget request to treat a patient with monkeypox in the US. The company's shares surged 43% on Friday before paring gains to close 13% lower on the Nasdaq on Monday, and another 15.5% on Tuesday. SIGA stock remains up 26.5% over the past 5 days of trading. SIGA also stands to benefit from TPOXX’s use in Canada and Europe, where cases of moneypox were detected in recent weeks. Europe has already approved the use of TPOXX against monkeypox, cowpox, and complications from immunization with vaccinia, the company said. Growing monkeypox threat Monkeypox, first discovered in 1958, is a viral illness that first occurred in colonies of monkeys. The first human case of the virus was recorded in the Democratic Republic of Congo in 1970, according to the US Centers for Disease Control and Prevention. The virus can cause symptoms like fever, body aches, swollen lymph nodes and bumpy rashes. Cases of monkeypox have so far been reported in at least 17 countries including the US, Canada, the UK, Spain, Portugal, France, Italy and Australia. Big pharma steps in SIGA and another vaccine maker in Denmark, Bavarian Nordic (CPH:BAVA), have kept samples of smallpox virus for research purposes in case of biological warfare. The emergence of monkeypox this year prompted both companies to start mass producing vaccines against smallpox to offer protection against monkeypox. CDC officials on Monday said the US is in the process of releasing Bavarian Nordic’s Jynneos vaccine doses to fight against monkeypox. The US has stockpiled more than 1,000 doses of the vaccine and CDC officials expect to boost their purchases in the coming weeks. Bavarian Nordic’s shares on the Nasdaq Copenhagen surged to a four-month high on Monday. The Danish company on May 18 said the US government has already placed a $119 million order for the production of freeze-dried Jynneos vaccines, although deliveries are not expected until 2023 and 2024. Meanwhile, Moderna (NASDAQ:MRNA), which succeeded in developing vaccines against COVID-19, also started testing vaccines against monkeypox. The company on Tuesday said it is investigating potential vaccines against monkeypox in pre-clinical trials. No urgent need for mass vaccinations Although vaccines against monkeypox are already within reach just weeks into reports of an outbreak emerged, some experts and WHO officials say inoculations against monkeypox will not likely involve a mass campaign as the virus, unlike COVID-19, is not as contagious. Vaccinations would likely be focused only on people with close contact with infected individuals. "If a case is reported in the country, a public health SWAT team goes out, finds out who the close contacts are of that first case, and vaccinates just those close contacts, and not the entire city or suburb,” Dr. David Freedman, professor emeritus of infectious diseases at the University of Alabama, was quoted by Time magazine as saying.
NASDAQ:SIGA
by BlackBull_Markets
INNO Trades Steady, Outperforms the CSE25 and HMMJ Marijuana ETF$INNO.CN stock grew by +3.39% on Friday, stock opened at $0.590 and closed at $0.610, meanwhile price action is working above 20 EMA in daily chart that shows stock is bullish in nature and MACD is also showing strength in stock. RSI is close to par, indicating that current share price is fairly valued. The market cap of the company is 159.073M, and its average 3mo volume is 52k. Last week amidst pronounced downturns in major markets and indexes, INNO continued to trade steadily, and outperformed the CSE25 Composite Index alongside the TSX's HMMJ Marijuana ETF. Despite serious background volatility, the legalization of recreational cannabis use in New Jersey and its steadily progressing R&D pipeline are clear bullish indicators for INNO's LT potential
CSE:INNO
by BiotechBrandon
PFE: Sell Zone is 58-60Pfizer's W-4 bottomed right in our "Buy Zone" and has bounced 10% since. I expect Pfizer to continue to climb up to the $58-60 level over the coming 2 weeks or so. After that, Pfizer will pull back for it's larger degree W-2, which should bring price back to about the $50 level. We will have more clarity on pullback targets once W-5 tops, most likely in our "selling zone". The point is, this is not an idea time to start a position. I will be selling covered calls against my shares of Pfizer when we reach the selling zone, and will be looking to add shares for about $50 sometime in Late May/Early June.
NYSE:PFELong
by TomDaSpankEngine
Mid-cap Pharma Company might get a booster dose.Mid-cap Pharma Company might get a booster dose? The 31,177.59 Cr. worth mid-cap Pharma company, Laurus Labs Ltd. gave a massive 96% CAGR (3yrs.) in the past. The share price of the company made a high of Rs. 723.55 after which it saw a downturn is now giving signals of its trend reversal to Bullish. The share price of the company made an 'inverted Head and Shoulders' pattern which is a bullish trend reversal pattern. Also, the share price might also see a 50 & 100 EMA crossover in the next 1-3 trading session which again makes it a positive for traders & investors. In clear words, the target for the share is 665 - 685, with a mid-term view of 2- 12 weeks. The stock might retest the level of 550 - 560 (precisely Rs. 555) which would also make it the ultimate support. Also, please consult your financial advisor before entering into any trade. This piece of knowledge is shared only for educational purposes. Thank You & keep learning!
NSE:LAURUSLABSLong
by GautamNegi